LENZ
LENZ Therapeutics Inc
3.90$
+5.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -23.6% | +208.8% | -6.8% | +10.5% | -3.9% | -6.5% | +8.0% | -3.0% | +45.2% | -10.9% | -13.2% | |
| – | -25.2% | +222.2% | -8.0% | +10.7% | -4.0% | -6.6% | +8.0% | -3.1% | +45.6% | -11.0% | -13.1% | |
| – | -18.0% | +470.2% | -58.1% | -51.2% | -50.9% | +14.3% | +63.2% | -32.5% | -0.9% | -1.6% | -2.3% | |
| – | -25.4% | +224.2% | -8.0% | +10.7% | -3.7% | -7.2% | +8.0% | -3.5% | +44.6% | -11.6% | -14.9% | |
| – | – | – | – | – | – | – | – | – | – | +4.3% | +28.9% | |
| – | – | – | – | – | – | – | – | – | +209.4% | +19.1% | +17.8% | |
| – | +0.8% | -88.3% | -49.3% | -10.2% | +28.6% | -17.6% | +18.7% | +53.0% | +28.4% | +20.9% | -33.4% | |
| – | +9.9% | +2.0% | -54.6% | -10.2% | +35.0% | -17.7% | +21.3% | +56.9% | +29.9% | +21.8% | -33.3% | |
| – | +3.0% | +216.1% | +49.9% | -3.7% | -9.3% | -10.2% | -5.3% | +2.3% | -5.7% | -6.2% | – | |
| – | +10.9% | +24.9% | -38.2% | -37.3% | +54.1% | -14.0% | -22.0% | +51.5% | -3.6% | +162.3% | -39.2% | |
| – | – | – | -2.6% | +11.6% | -5.2% | -5.9% | +7.5% | -6.0% | +46.6% | -13.3% | -11.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.3% | -43.1% | +442.8% | +6.1% | +1.2% | +0.1% | +2.0% | +1.6% | +8.9% | +0.9% | +0.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.